Medtronic $MDT Secures FDA Clearance for New Surgical Instrument

Medtronic (NYSE: MDT) announced on Wednesday, September 16, 2026, that the U.S. Food and Drug Administration (FDA) has granted clearance for its LigaSure™ RAS Maryland jaw device. This instrument is now approved for use in conjunction with the Hugo™ robotic-assisted surgery (RAS) system.

The clearance signifies an expansion of the available instruments for the Hugo RAS system, integrating Medtronic's established vessel-sealing technology into robotic surgical procedures performed by U.S. surgeons.

### Money Play - Watch Medtronic ($MDT+WL) as it absorbs news of FDA clearance for its new surgical instrument, potentially signaling increased utility for its Hugo RAS system.

## Catalyst Analysis: FDA Clearance The U.S. Food and Drug Administration's clearance of the LigaSure™ RAS Maryland jaw device for Medtronic's Hugo™ RAS system marks a significant regulatory achievement. This authorization allows for the integration of Medtronic's proprietary vessel-sealing technology into robotic-assisted surgical interventions.

## Technical Analysis & Key Risk Watch

67.13 · R1 ## Technical Analysis & Key Risk Watch 65.61 · last ## Technical Analysis & Key Risk Watch 65.36 · S1 ## Technical Analysis & Key Risk Watch 65.11 · S2 ## Technical Analysis & Key Risk Watch 62.62.

Medtronic ($MDT+WL) is trading at $94.17 with an RSI14 of 60.6, indicating a relatively balanced market sentiment. Key resistance levels to watch are $94.53 and $95.41, while support is found at $92.66 and $91.73.

## Impact on Healthcare Technology This development could enhance Medtronic's competitive position in the robotic-assisted surgery market by broadening the range of instruments available for its Hugo system. The availability of trusted sealing technology is crucial for surgeons performing complex robotic procedures.